Cytomegalovirus immune globulin - MedImmune

Alternative Names: CMV-IGIV; CytoGam

Latest Information Update: 22 Apr 2013

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator MedImmune
Class Antivirals; Immunoglobulins
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Marketed Cytomegalovirus infections

Most Recent Events

30 Apr 2012 CSL initiates enrolment in a phase III trial for Cytomegalovirus infections (prevention of congenital CMV) in the US (NCT01376778)
19 Jun 2007 MedImmune has been acquired by AstraZeneca
08 Jan 2007 ZLB Behring is now called CSL Pharma

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.